Cryptococcus neoformans: The Model Organism for Yeast Antifungal Drug Susceptibility Testing

Mycopathologia

Volumn 173, Issue 5-6, 2012, Pages 435-443

  Bauer, Madeline ^a   Thomas, Ann M ^b   Larsen, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

Data visualization tools; In vitro clinical correlations; Loess regression; Patient specific treatment selection; Robust response surface design

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ARTICLE; CHEMISTRY; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DRUG COMBINATION; DRUG EFFECT; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA; DRUG COMBINATIONS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS;

FILOBASIDIELLA NEOFORMANS;

EID: 84860592390     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9524-0     Document Type: Article

References (32)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23(4): 525-30.
2. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010; 10: 67.
3. Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, Robertson VJ, Musvaire P, Mason PR. Impact of HIV infection on meningitis in Harare: a prospective study of 406 predominantly adult patients. AIDS. 2000; 14: 1401-7.
4. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Mbwvinji M, Molyneux ME, Read RC. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis. 2000; 21: 53-7.
5. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. Clin Infect Dis. 2001; 32(6): 955-62.
6. Kong BN, Harwell JI, Suos P, Lynen L, Mohiuddin S, Reinert S, Pugatch D. Opportunistic infections and HIV clinical disease stage among patients presenting for care in Phnom Penh, Cambodia. Southeast Asian J Trop Med Public Health. 2007; 38(1): 62-8.
7. Klotz SA, Nguyen HC, van Pham T, Nguyen LT, Ngo DT, Vu SN. Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. Int J STD AIDS. 2007; 18(7): 482-5.
8. Harrison TS. The burden of HIV-associated cryptococcal disease. AIDS. 2009; 23(4): 531-2.
9. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(3): 291-322.
10. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard-3rd edn, M27-A3, CLSI, Wayne, PA (2008).
11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: Third information supplement. CLSI document M27-S3 (ISBN 1-56238-667-0). 28: M27-S3 (2008).
12. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis. 2011; 69(1): 45-50.
13. Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, Lortholary O, Dromer F, the French Cryptococcosis Study Group. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother. 2006; 50(7): 2464-70.
14. Robinson PA, Bauer M, Leal MA, Evans SG, Holtom PD, Diamond DA, Leedom JM, Larsen RA. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999; 28(1): 82-92.
15. Larsen RA, Bauer M, Brouwer AE, Sanchez A, Thomas AM, Rajanuwong A, Chierakul W, Peacock SJ, Day N, White NJ, Rinaldi MG, Harrison TS. In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2007; 51(1): 343-5.
16. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, McCutchan JA, Larsen RA. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008; 46(4): 393-5.
17. Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC, Rinaldi MG, Graybill JR. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1996; 40(9): 2178-82.
18. Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK, Thomas AM, Ding JC, Najvar L, Graybill JR, Larsen RA. Amphotericin B Colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother. 1998; 42(3): 528-33.
19. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B combined with fluconazole a potent combination for treatment of cryptococcal meningitis. Antimicrob Agents Chemother. 2004; 48(3): 985-91.
20. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother. 2003; 47(7): 2373-5.
21. Ding JC, Bauer M, Diamond DM, Leal MA, Johnson D, Williams BK, Thomas AM, Najvar L, Graybill JR, Larsen RA. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother. 1997; 41(7): 1589-93.
22. Larsen RA, Bauer M, Thomas AM, Sanchez A, Citron D, Rathbun M, Harrison TS. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob Agents Chemother. 2005; 49(8): 3297-301.
23. Cleveland WS. Visualizing data. Summit: Hobart Press; 1993.
24. Thomas AM. Bauer M. Graybill JR. Larsen RA. Experimental designs for evaluating combination therapies using loess regression. In: Proceedings of 1999 JSM American Statistical Association, Alexandria, VA.
25. Tibco Spotfire S + 8 for Windows. TIBCO Software Inc., Seattle, WA, 2011.
26. Venables WN, Ripley BD. Modern applied statistics with S-PLUS. 4th ed. New York: Springer; 2002.
27. Cleveland WS, et al. Local regression models. In: Chambers JM, Hastie T, editors. Statistical models in S. London: Chapman and Hall; 1991. p. 309-76.
28. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, Wall E, Andia I, Jaffar S, Harrison TS. Dose response effect of high dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008; 47(12): 1556-61.
29. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, Rebe K, Loyse A, Jarvis J, Bekker LG, Wood R, Limmathurotsakul D, Chierakul W, Stepniewska K, White NJ, Jaffar S, Harrison TS. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009; 49(5): 702-9.
30. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. Combination antifungal therapies for HIV-associated cryptococcal meningitis: feasibility and power of quantitative CSF cultures to determine fungicidal activity. Lancet. 2004; 363(9423): 1764-7.
31. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect. 2001; 43(4): 226-33.
32. Larsen RA, Sanchez A, Bauer M, Wuthiekanun V, Peacock S, Pitisuttithun P, Fothergill AW, Rinaldi MG, Bustamante B, Thomas AM, Altomstone R, White NJ. Correlation of susceptibility testing of C. neoformans to amphotericin B with clinical outcome. Antimicrob Agents Chemother. 2011; 55(12): 5624.